Source: yahoo_news
Source ID: yahoo:87f3a8309cf803feb987c9536937f93a:OSTX
URL: https://finance.yahoo.com/healthcare/articles/os-therapies-achieves-statistically-significant-123000018.html?.tsrc=rss
Symbol: (OSTX)
Published: 2026-10-06 08:30:00 EDT
Time precision: minute
Title: OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial

Leading Clinical Stage Oncology Company Releases Significant Findings from OST-HER2-Treated Patients72.7 percent three-year overall survival vs. 45.8 percent comparable combined historical control (p = 0.0006)Company preparing to complete submissions for early market access in the U.S., U.K., Europe and AustraliaWHO recently accepted the proprietary brand name Herlystic™ for OST-HER2 (daznelimgene lisbac).Grasonville, Maryland--(Newsfile Corp. - October 6, 2026) - OS Therapies, Inc. (NYSE...